{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:07:40Z","timestamp":1787065660681,"version":"build-2736575974"},"reference-count":192,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.phrs.2019.104389","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T19:59:04Z","timestamp":1565639944000},"page":"104389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Biologics in Sj\u00f6gren's syndrome"],"prefix":"10.1016","volume":"147","author":[{"given":"Charalampos","family":"Skarlis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Marketos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clio P.","family":"Mavragani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2019.104389_bib0005","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1503\/cmaj.122037","article-title":"Sj\u00f6gren syndrome (Review)","volume":"186","author":"Mavragani","year":"2014","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.phrs.2019.104389_bib0010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jaut.2010.06.012","article-title":"Activation of the type I interferon pathway in primary Sjogren's syndrome","volume":"35","author":"Mavragani","year":"2010","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.phrs.2019.104389_bib0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","article-title":"Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis","volume":"63","author":"Nezos","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.phrs.2019.104389_bib0020","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/1744666X.2018.1519396","article-title":"Interferon activation in primary Sj\u00f6gren's syndrome: recent insights and future perspective as novel treatment target","volume":"14","author":"Bodewes","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.180392","article-title":"Primary versus secondary Sj\u00f6gren syndrome: is it time to reconsider these terms?","volume":"46","author":"Mavragani","year":"2019","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.berh.2010.01.011","article-title":"Chronic widespread pain in the spectrum of rheumatological diseases","volume":"25","author":"Atzeni","year":"2011","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0035","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jaut.2013.10.002","article-title":"Biomarkers of lymphoma in Sj\u00f6gren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study","volume":"51","author":"Quartuccio","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.phrs.2019.104389_bib0040","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","article-title":"Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sj\u00f6gren's syndrome","volume":"46","author":"Ioannidis","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104389_bib0045","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0049-0172(00)80016-5","article-title":"Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome","volume":"29","author":"Skopouli","year":"2000","journal-title":"Sem. Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104389_bib0050","first-page":"1","article-title":"Predicting the risk for lymphoma development in Sjogren syndrome","volume":"95","author":"Fragkioudaki","year":"2016","journal-title":"Medicine (United States)"},{"key":"10.1016\/j.phrs.2019.104389_bib0055","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/art.39518","article-title":"Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sj\u00f6gren's syndrome","volume":"68","author":"Nocturne","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0060","article-title":"Monoclonal gammopathy and risk of lymphoma and multiple myeloma in patients with primary Sj\u00f6gren's syndrome","volume":"68","author":"Tomi","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/rheumatology\/34.4.326","article-title":"Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sj\u00f6gren's syndrome","volume":"34","author":"Boumba","year":"1995","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2019.104389_bib0070","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/ard.2009.115378","article-title":"Cytokines in Sjogren's syndrome: potential therapeutic targets","volume":"69","author":"Roescher","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0075","first-page":"970","article-title":"Salivary cytokine profiles in primary Sj\u00f6gren's syndrome differ from those in non-sj\u00f6gren sicca in terms of TNF-\u03b1 levels and Th-1\/Th-2 ratios","volume":"29","author":"Kang","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0080","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3343\/alm.2019.39.1.76","article-title":"Role of salivary immune parameters in patients with primary Sj\u00f6gren's syndrome","volume":"39","author":"Hung","year":"2019","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.phrs.2019.104389_bib0085","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1076\/ceyr.19.3.201.5309","article-title":"Altered cytokine balance in the tear fluid and conjunctiva of patients with Sj\u00f6gren's syndrome keratoconjunctivitis sicca","volume":"19","author":"Pflugfelder","year":"1999","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.phrs.2019.104389_bib0090","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1586\/1744666X.2015.1027151","article-title":"Iguratimod for the treatment of rheumatoid arthritis in Japan","volume":"11","author":"Tanaka","year":"2015","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0095","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1358\/dot.2012.48.9.1855758","article-title":"Iguratimod: a new disease-modifying antirheumatic drug","volume":"48","author":"Mucke","year":"2012","journal-title":"Drugs Today (Barcelona, Spain: 1998)"},{"key":"10.1016\/j.phrs.2019.104389_bib0100","first-page":"1","article-title":"The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis","author":"Suto","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0105","article-title":"Therapeutic efficacy of iguratimod in patients with primary Sjogren's syndrome \u2013 ACR Meeting Abstracts","volume":"18","author":"Zhang","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0110","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrn2297","article-title":"From inflammation to sickness and depression: when the immune system subjugates the brain","volume":"9","author":"Dantzer","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2019.104389_bib0115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/acr.22720","article-title":"Fatigue in primary Sj\u00f6gren's syndrome: clinical, laboratory, psychometric, and biologic associations","volume":"68","author":"Karageorgas","year":"2016","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.phrs.2019.104389_bib0120","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1600-0404.2011.01530.x","article-title":"Primary Sjogren's syndrome: cognitive symptoms, mood, and cognitive performance","volume":"125","author":"Segal","year":"2012","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.phrs.2019.104389_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/brb3.586","article-title":"Cognition, depression, fatigue, and quality of life in primary Sj\u00f6gren's syndrome: correlations","volume":"6","author":"Ko\u00e7er","year":"2016","journal-title":"Brain Behav."},{"key":"10.1016\/j.phrs.2019.104389_bib0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030123","article-title":"Interleukin-1 inhibition and fatigue in primary sj\u00f6gren's syndrome \u2013 a double blind, randomised clinical trial","volume":"7","author":"Norheim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.104389_bib0135","first-page":"1957","article-title":"Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease","volume":"19","author":"Vijmasi","year":"2013","journal-title":"Mol. Vis."},{"key":"10.1016\/j.phrs.2019.104389_bib0140","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2004.08.004","article-title":"Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review","volume":"4","author":"Atzeni","year":"2005","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.phrs.2019.104389_bib0145","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of Infliximab in primary Sj\u00f6gren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj\u00f6gren's Syndrome (TRIPSS)","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104389_bib0150","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4274\/tjo.48379","article-title":"Effect of systemic infliximab therapy in patients with Sj\u00f6gren's syndrome","volume":"45","author":"T\u00fcrko\u011flu","year":"2015","journal-title":"Turk Oftalmoloiji Dergisi"},{"key":"10.1016\/j.phrs.2019.104389_bib0155","first-page":"96","article-title":"Etanercept in the treatment of patients with primary Sj\u00f6gren's syndrome: a pilot study","volume":"31","author":"Zandbelt","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0160","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","article-title":"Etanercept in Sj\u00f6gren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial","volume":"50","author":"Sankar","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104389_bib0165","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/ard.2007.077891","article-title":"Lack of efficacy of etanercept in Sj\u00f6gren syndrome correlates with failed suppression of tumour necrosis factor \u03b1 and systemic immune activation","volume":"67","author":"Moutsopoulos","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0170","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1002\/art.23062","article-title":"Augmented interferon-\u03b1 pathway activation in patients with Sj\u00f6gren's syndrome treated with etanercept","volume":"56","author":"Mavragani","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104389_bib0175","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/1756-185X.13086","article-title":"Pyoderma gangrenosum in Sj\u00f6gren's syndrome and its successful treatment with topical application of etanercept","volume":"20","author":"Haridas","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0180","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/1759720X18798462","article-title":"New insights and long-term safety of tocilizumab in rheumatoid arthritis","author":"Jones","year":"2018","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0185","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/rheumatology\/kex424","article-title":"Large-vessel giant cell arteritis: diagnosis, monitoring and management","author":"Koster","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2019.104389_bib0190","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0195","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.pediatrneurol.2017.05.015","article-title":"First pediatric patient with neuromyelitis optica and Sj\u00f6gren syndrome successfully treated with tocilizumab","volume":"73","author":"Marino","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.phrs.2019.104389_bib0200","first-page":"1","article-title":"Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: a case report","volume":"7595","author":"Komai","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0205","first-page":"2014","article-title":"Tocilizumab for refractory organising pneumonia associated with Sj\u00f6gren's disease","author":"Justet","year":"2015","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.phrs.2019.104389_bib0210","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/BOR.0b013e328349fd30","article-title":"Activation of the type I interferon pathway in primary Sj\u00f6gren's syndrome","volume":"23","author":"Vakaloglou","year":"2011","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0215","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1586\/1744666X.2014.876364","article-title":"Type I IFN signature in primary Sj\u00f6gren's syndrome patients","volume":"10","author":"Brkic","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0220","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","article-title":"Prevalence of interferon type I signature in CD14 monocytes of patients with Sj\u00f6gren's syndrome and association with disease activity and BAFF gene expression","volume":"72","author":"Brkic","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0225","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/art.39204","article-title":"Molecular subsetting of interferon pathways in Sj\u00f6gren's syndrome","volume":"67","author":"Hall","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0230","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1073\/pnas.0510837103","article-title":"Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome","volume":"103","author":"Gottenberg","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.phrs.2019.104389_bib0235","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2249.2002.01869.x","article-title":"The Th1\/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome","volume":"128","author":"Mitsias","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0240","doi-asserted-by":"crossref","first-page":"195ra96","DOI":"10.1126\/scitranslmed.3005727","article-title":"NCR3\/NKp30 contributes to pathogenesis in primary Sjogren's syndrome","volume":"5","author":"Rusakiewicz","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2019.104389_bib0245","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/art.39795","article-title":"Expression of long interspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease","volume":"68","author":"Mavragani","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0250","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0961203316678675","article-title":"Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study","volume":"26","author":"Burge","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.phrs.2019.104389_bib0255","first-page":"1771","article-title":"Op0202 effect of Rslv-132 on fatigue in patients with primary Sj\u00f6gren'S syndrome \u2013 results of a phase II randomised, double-blind, placebo-controlled, proof of concept study","author":"Fisher","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0260","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.0001-2815.2004.00290.x","article-title":"The LILR family: modulators of innate and adaptive immune pathways in health and disease","volume":"64","author":"Brown","year":"2004","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.phrs.2019.104389_bib0265","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2567.2009.03097.x","article-title":"Regulation of T-cell immunity by leucocyte immunoglobulin-like receptors: innate immune receptors for self on antigen-presenting cells","volume":"127","author":"Anderson","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.phrs.2019.104389_bib0270","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.0105-2896.2009.00867.x","article-title":"Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells","volume":"234","author":"Cao","year":"2010","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.phrs.2019.104389_bib0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089414","article-title":"Effect of immunoglobin-like transcript 7 cross-linking on plasmacytoid dendritic cells differentiation into antigen-presenting cells","volume":"9","author":"Tavano","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.104389_bib0280","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0285","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/ar625","article-title":"Systemic lupus erythematosus and the type I interferon system","volume":"5","author":"R\u00f6nnblom","year":"2003","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2019.104389_bib0290","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0295","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaut.2018.02.001","article-title":"TBK1: a key regulator and potential treatment target for interferon positive Sjogren's syndrome, systemic lupus erythematosus and systemic sclerosis","volume":"91","author":"Bodewes","year":"2018","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.phrs.2019.104389_bib0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-9255-4-5","article-title":"The role of the purinergic P2X7receptor in inflammation","volume":"4","author":"Lister","year":"2007","journal-title":"J. Inflamm."},{"key":"10.1016\/j.phrs.2019.104389_bib0305","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2016.03.046","article-title":"Inflammasome complexes: emerging mechanisms and effector functions","volume":"165","author":"Rathinam","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2019.104389_bib0310","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/joim.12115","article-title":"The P2X7receptor-inflammasome complex has a role in modulating the inflammatory response in primary Sj\u00f6gren's syndrome","volume":"274","author":"Baldini","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.phrs.2019.104389_bib0315","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/joim.12631","article-title":"The P2X7 receptor\u2013NLRP3 inflammasome complex predicts the development of non-Hodgkin's lymphoma in Sj\u00f6gren's syndrome: a prospective, observational, single-centre study","volume":"282","author":"Baldini","year":"2017","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.phrs.2019.104389_bib0320","doi-asserted-by":"crossref","first-page":"16626","DOI":"10.1074\/jbc.M117.790741","article-title":"P2X7 receptor antagonism prevents IL-1 release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy","volume":"292","author":"Khalafalla","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2019.104389_bib0325","first-page":"473","article-title":"Cathepsin S inhibitors as novel immunomodulators","volume":"6","author":"Thurmond","year":"2005","journal-title":"Curr. Opin. Invest. Drugs (London, England: 2000)"},{"key":"10.1016\/j.phrs.2019.104389_bib0330","first-page":"1","article-title":"Longitudinal analysis of tear cathepsin S activity levels in male non-obese diabetic mice suggests its potential as an early stage biomarker of Sj\u00f6gren's syndrome","author":"Janga","year":"2018","journal-title":"Biomarkers"},{"key":"10.1016\/j.phrs.2019.104389_bib0335","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/art.38633","article-title":"Tear cathepsin s as a candidate biomarker for Sj\u00f6gren's syndrome","volume":"66","author":"Hamm-Alvarez","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0340","first-page":"1","article-title":"Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sj\u00f6gren syndrome","volume":"2","author":"Hargreaves","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2019.104389_bib0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exer.2017.05.006","article-title":"Degradation of proteoglycan 4\/lubricin by cathepsin S: potential mechanism for diminished ocular surface lubrication in Sj\u00f6gren's syndrome","volume":"161","author":"Regmi","year":"2017","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.phrs.2019.104389_bib0350","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1172\/JCI0214682","article-title":"Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity","volume":"110","author":"Saegusa","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2019.104389_bib0355","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nrneph.2013.183","article-title":"Targeting co-stimulatory pathways: transplantation and autoimmunity","volume":"10","author":"Ford","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.phrs.2019.104389_bib0360","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1600-065X.2009.00769.x","article-title":"Yin-Yang of costimulation: crucial controls of immune tolerance and function","volume":"229","author":"Nurieva","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.phrs.2019.104389_bib0365","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"Pillars article: CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/j.phrs.2019.104389_bib0370","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.smim.2011.04.002","article-title":"Costimulatory pathways in transplantation","volume":"23","author":"Pilat","year":"2011","journal-title":"Sem. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0375","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jaut.2012.01.002","article-title":"Pathogenesis of Sj\u00f6gren's syndrome: what we know and what we should learn","volume":"39","author":"Tzioufas","year":"2012","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.phrs.2019.104389_bib0380","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/366076a0","article-title":"B70 antigen is a second ligand for CTLA-4 and CD28","volume":"366","author":"Azuma","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2019.104389_bib0385","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1074-7613(94)80021-9","article-title":"Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors [published erratum appears in Immunity 1995 Feb;2(2):following 203]","volume":"1","author":"Linsley","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/j.phrs.2019.104389_bib0390","first-page":"170","article-title":"CTLA-4 in autoimmune diseases \u2013 a general susceptibility gene to autoimmunity?","volume":"1","author":"Kristiansen","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2019.104389_bib0395","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-med-043015-123313","article-title":"Mechanisms and new strategies for primary Sj\u00f6gren's syndrome","volume":"68","author":"Mavragani","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.phrs.2019.104389_bib0400","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.immunol.19.1.225","article-title":"Complexities of CD28\/B7: CTLA-4 costimulatory pathways in autoimmunity","volume":"19","author":"Salomon","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0405","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJM199806183382506","article-title":"The role of T-cell costimulatory activation pathways in transplant rejection","volume":"338","author":"Sayegh","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104389_bib0410","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.180.6.3815","article-title":"A novel B7-2 (CD86) splice variant with a putative negative regulatory role","volume":"180","author":"Kapsogeorgou","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0415","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.1365-2249.2000.01121.x","article-title":"Treatment with anti-CD86 costimulatory molecule prevents the autoimmune lesions in murine Sjogren's syndrome (SS) through up-regulated Th2 response","volume":"119","author":"Saegusa","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0420","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s40265-016-0659-z","article-title":"Treating the underlying pathophysiology of primary Sj\u00f6gren syndrome: recent advances and future prospects","volume":"76","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.104389_bib0425","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sj\u00f6gren's syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0430","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/acr.22052","article-title":"Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sj\u00f6gren's syndrome: a pilot study","volume":"65","author":"Adler","year":"2013","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.phrs.2019.104389_bib0435","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/art.40165","article-title":"Attenuation of follicular helper T cell-dependent b cell hyperactivity by abatacept treatment in primary Sj\u00f6gren's syndrome","volume":"69","author":"Verstappen","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0440","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/14397595.2017.1349234","article-title":"Diffusion-weighted magnetic resonance imaging of parotid glands before and after abatacept therapy in patients with Sj\u00f6gren's syndrome associated with rheumatoid arthritis: utility to evaluate and predict response to treatment","volume":"28","author":"Takahashi","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0445","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/14397595.2014.958892","article-title":"Usefulness of MR imaging of the parotid glands in patients with secondary Sj\u00f6gren's syndrome associated with rheumatoid arthritis","volume":"25","author":"Yokosawa","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0450","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/14397595.2014.951144","volume":"25","author":"Tsuboi","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0455","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3109\/14397595.2016.1158773","article-title":"Effectiveness of abatacept for patients with Sj\u00f6gren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sj\u00f6gren's syndrome Endocrinopathy) trial","volume":"26","author":"Tsuboi","year":"2016","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0460","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-eular.970","article-title":"Op0045 Abatacept treatment of patients with early active primary Sj\u00f6gren's syndrome \u2013 a randomized, double-blind placebo-controlled phase","author":"Spijkervet","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0465","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/art.40059","article-title":"Enhanced Bruton's tyrosine kinase activity in peripheral blood B lymphocytes from patients with autoimmune disease","volume":"69","author":"Corneth","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0470","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"Supporting online material CTLA-4 control over Foxp3 + regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.104389_bib0475","doi-asserted-by":"crossref","first-page":"17ra10","DOI":"10.1126\/scitranslmed.3000116","article-title":"Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation","volume":"2","author":"Poirier","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2019.104389_bib0480","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s12026-016-8880-0","article-title":"The role of B7 family costimulatory molecules and indoleamine 2,3-dioxygenase in primary Sj\u00f6gren's syndrome and systemic sclerosis","volume":"65","author":"Leg\u00e1ny","year":"2017","journal-title":"Immunol. Res."},{"key":"10.1016\/j.phrs.2019.104389_bib0485","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/16717","article-title":"ICOS is an inducible T-cell co-stimulator structrally and functionally related to CD28","volume":"397","author":"Hutloff","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2019.104389_bib0490","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/art.40479","article-title":"Brief report: a randomized, double-blind, parallel-group, placebo-controlled, multiple-dose study to evaluate AMG 557 in patients with systemic lupus erythematosus and active lupus arthritis","volume":"70","author":"Cheng","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0495","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.67.1.2","article-title":"CD40-CD40 ligand","volume":"67","author":"Van Kooten","year":"2000","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.phrs.2019.104389_bib0500","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1073\/pnas.89.14.6550","article-title":"A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells","volume":"89","author":"Noelle","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.phrs.2019.104389_bib0505","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/1074-7613(94)90095-7","article-title":"The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation","volume":"1","author":"Kawabe","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/j.phrs.2019.104389_bib0510","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jaut.2006.02.002","article-title":"Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases","volume":"26","author":"Goules","year":"2006","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.phrs.2019.104389_bib0515","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/sji.12121","article-title":"Upregulation of membrane-bound CD40L on CD4+ T cells in women with primary Sj\u00f6gren's syndrome","volume":"79","author":"Belkhir","year":"2014","journal-title":"Scand. J. Immunol."},{"issue":"Suppl. 10","key":"10.1016\/j.phrs.2019.104389_bib0520","first-page":"69","article-title":"The novel anti-CD40 monoclonal antibody CFZ533 shows beneficial effects in patients with primary Sj\u00f6gren's syndrome: a phase IIa double-blind, placebo-controlled randomized trial \u2013 ACR Meeting Abstracts","volume":"69","author":"Fisher","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0525","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-eular.4277","article-title":"Subcutaneous dosing of the novel anti-CD40 antibody iscalimab achieves target drug exposure and clinical efficacy in primary Sj\u00f6gren's syndrome; results of a phase IIa randomised open label two arm parallel group trial","author":"Fisher","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0530","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2018-213929","article-title":"Blockade of CD40-CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD\/ShiLtJ mouse model of Sj\u00f6gren's syndrome","volume":"78","author":"Wieczorek","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0535","series-title":"Live Imaging of LFA-1-Dependent T-Cell Motility and Stop Signals","first-page":"191","author":"Wiemer","year":"2011"},{"key":"10.1016\/j.phrs.2019.104389_bib0540","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.exer.2003.10.024","article-title":"ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sj\u00f6grens syndrome-like MRL\/lpr mice","volume":"78","author":"Gao","year":"2004","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.phrs.2019.104389_bib0545","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2249.1995.tb03790.x","article-title":"Prevention of adoptive transfer of murine Sj\u00f6gren's syndrome into severe combined immunodeficient (SCID) mice by antibodies against intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1)","volume":"102","author":"Hayashi","year":"1995","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0550","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1046\/j.1365-2249.2001.01500.x","article-title":"Activation of epithelial and myoepithelial cells in the salivary glands of patients with Sj\u00f6gren's syndrome: high expression of intercellular adhesion molecule-1 (ICAM.1) in biopsy specimens and cultured cells","volume":"124","author":"Kapsogeorgou","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0555","doi-asserted-by":"crossref","first-page":"e19962","DOI":"10.1371\/journal.pone.0019962","article-title":"Effect of soluble ICAM-1 on a Sj\u00f6gren's syndrome-like phenotype in NOD mice is disease stage dependent","volume":"6","author":"Roescher","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.104389_bib0560","doi-asserted-by":"crossref","DOI":"10.1089\/jop.2018.0047","article-title":"Suppression of Th1-mediated keratoconjunctivitis sicca by lifitegrast","author":"Guimaraes de Souza","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2019.104389_bib0565","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00296-016-3436-0","article-title":"Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies","volume":"36","author":"Elyoussfi","year":"2016","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.phrs.2019.104389_bib0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0059868","article-title":"Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sj\u00f6gren's syndrome. Data at enrollment in the prospective ASSESS cohort","volume":"8","author":"Gottenberg","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2019.104389_bib0575","first-page":"6","article-title":"Effects of rituximab therapy on quality of life in patients with primary Sj\u00f6gren's syndrome","author":"Morvan","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12013-008-9036-1","article-title":"The BLyS family: toward a molecular understanding of B cell homeostasis","volume":"53","author":"Treml","year":"2009","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.phrs.2019.104389_bib0585","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-3083.2007.02049.x","article-title":"B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sj\u00f6gren's syndrome","volume":"67","author":"Lavie","year":"2008","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0590","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/embo-reports\/kve198","article-title":"Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase","volume":"2","author":"L\u00f3pez-Fraga","year":"2001","journal-title":"EMBO Rep."},{"key":"10.1016\/j.phrs.2019.104389_bib0595","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.clim.2016.06.007","article-title":"BAFF overexpression increases lymphocytic infiltration in Sj\u00f6gren's target tissue, but only inefficiently promotes ectopic B-cell differentiation","volume":"169","author":"Ding","year":"2016","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0600","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2019.104389_bib0605","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/rheumatology\/kev420","article-title":"Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sj\u00f6gren's syndrome","volume":"55","author":"Thompson","year":"2016","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1016\/j.phrs.2019.104389_bib0610","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.coi.2005.04.005","article-title":"The role of APRIL and BAFF in lymphocyte activation","volume":"17","author":"Schneider","year":"2005","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0615","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0620","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.62.2.168","article-title":"The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sj\u00f6gren's syndrome","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0625","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/rheumatology\/keu417","article-title":"Biologic treatment in Sj\u00f6gren's syndrome","volume":"54","author":"Sada","year":"2015","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1016\/j.phrs.2019.104389_bib0630","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaut.2013.04.005","article-title":"B-cell activating factor genetic variants in lymphomagenesis associated with primary Sj\u00f6gren's syndrome","volume":"51","author":"Nezos","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.phrs.2019.104389_bib0635","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/rheumatology\/kes180","article-title":"BLyS upregulation in Sj\u00f6gren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands","author":"Quartuccio","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2019.104389_bib0640","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1002\/art.39231","article-title":"A BAFF receptor His159Tyr mutation in Sj\u00f6gren's syndrome-related lymphoproliferation","volume":"67","author":"Papageorgiou","year":"2015","journal-title":"Arthritis Rheumatol. (Hoboken, N.J.)"},{"key":"10.1016\/j.phrs.2019.104389_bib0645","first-page":"311","article-title":"Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sj\u00f6gren's syndrome: follow-up after the end of the phase II open-label BELISS study","volume":"34","author":"Quartuccio","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0650","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren's syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0655","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/rheumatology\/kev005","article-title":"Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome","volume":"54","author":"Pontarini","year":"2015","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1016\/j.phrs.2019.104389_bib0660","first-page":"2249","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sj\u00f6gren's syndrome: the BELISS open-label phase II study","volume":"54","author":"De Vita","year":"2015","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1016\/j.phrs.2019.104389_bib0665","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-015-0750-y","article-title":"Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sj\u00f6gren's syndrome: results of the BELISS study","volume":"17","author":"Seror","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2019.104389_bib0670","first-page":"719","article-title":"Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sj\u00f6gren's syndrome","author":"Quartuccio","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0675","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/path.1533","article-title":"Expression of BAFF(BLyS) in T cells infiltrating labial salivary glands from patients with Sj\u00f6gren's syndrome","volume":"202","author":"Lavie","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.phrs.2019.104389_bib0680","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","article-title":"Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy","volume":"174","author":"Gong","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0685","first-page":"490","article-title":"Sequential therapy with belimumab followed by rituximab in Sj\u00f6gren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy","volume":"32","author":"De Vita","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0690","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-eular.5840","article-title":"THU0313 double-blind, randomized study of VAY736 Single dose treatment in patients with Primary Sj\u00f6gren's Syndrome (PSS)","volume":"75","author":"D\u00f6rner","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0695","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary sj\u00f6gren's syndrome with ianalumab (vay736) targeting b cells by baff receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0700","article-title":"Immunosignature-based diagnosis and prediction of therapeutic response enables retrospective patient stratification in a phase IIa clinical trial for VAY736 in primary Sj\u00f6gren's syndrome \u2013 ACR Meeting Abstracts","volume":"69","author":"Gerwien","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0705","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4049\/jimmunol.135.2.973","article-title":"The B cell surface molecule B1 is functionally linked with B cell activation and differentiation","volume":"135","author":"Tedder","year":"1985","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.phrs.2019.104389_bib0710","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2017.03.012","article-title":"FcRL4+ B-cells in salivary glands of primary Sj\u00f6gren's syndrome patients","volume":"81","author":"Haacke","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.phrs.2019.104389_bib0715","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/cei.12771","article-title":"Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sj\u00f6gren's syndrome: a pilot study","volume":"184","author":"Alunno","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0720","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0725","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.phrs.2019.104389_bib0730","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren's syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0735","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/annrheumdis-2011-200460","article-title":"Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sj\u00f6gren's syndrome treated with rituximab","volume":"71","author":"Meiners","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0740","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2008.092601","article-title":"Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment","volume":"68","author":"Meijer","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0745","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104389_bib0750","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sj\u00f6gren's syndrome an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104389_bib0755","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","article-title":"Club Rhumatismes et Inflammations and the French Society of Rheumatology, Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry","volume":"72","author":"Gottenberg","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0760","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/acr.22974","article-title":"Severe health-related quality of life impairment in active primary Sj\u00f6gren's syndrome and patient-reported outcomes: data from a large therapeutic trial","volume":"69","author":"Cornec","year":"2017","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.phrs.2019.104389_bib0765","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2474-15-21","article-title":"The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sj\u00f6gren's Syndrome","volume":"15","author":"Brown","year":"2014","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.phrs.2019.104389_bib0770","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/annrheumdis-2017-212268","article-title":"Effect of rituximab on a salivary gland ultrasound score in primary Sj\u00f6gren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy","volume":"77","author":"Fisher","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0775","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1074-7613(00)80270-8","article-title":"CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice","volume":"5","author":"Sato","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.phrs.2019.104389_bib0780","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","article-title":"Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma","volume":"21","author":"Leonard","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2019.104389_bib0785","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/art.37818","article-title":"CD22 ligation inhibits downstream B cell receptor signaling and Ca2+ flux upon activation","volume":"65","author":"Sieger","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104389_bib0790","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1158\/1078-0432.CCR-04-0294","article-title":"Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I\/II clinical trial results","volume":"10","author":"Leonard","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2019.104389_bib0795","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.4049\/jimmunol.177.5.3063","article-title":"CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo","volume":"177","author":"Haas","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0800","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, multicentre study","author":"Wallace","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0805","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/acr.22694","article-title":"Long-term safety and efficacy of epratuzumab in the treatment of moderate-to-severe systemic lupus erythematosus: results from an open-label extension study","volume":"68","author":"Wallace","year":"2016","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.phrs.2019.104389_bib0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar2018","article-title":"Epratuzumab (humanised anti-CD22 antibody) in primary Sj\u00f6gren's syndrome: an open-label phase I\/II study","volume":"8","author":"Steinfeld","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2019.104389_bib0815","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4195.4195","article-title":"An ongoing open-label phase 1\/2 study of INCB050465, a selective PI3K\u03b4 inhibitor, in patients with previously treated B-cell malignancies","volume":"128","author":"Phillips","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2019.104389_bib0820","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3324\/haematol.2014.119123","article-title":"The role of b-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia","volume":"100","author":"Wiestner","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.phrs.2019.104389_bib0825","first-page":"1053","article-title":"Phosphatidylinositol-3-kinase delta pathway a novel therapeutic target for Sjogren's syndrome","volume":"67","author":"Nayar Saba","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0830","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/annrheumdis-2017-212619","article-title":"Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sj\u00f6gren's syndrome","volume":"78","author":"Nayar","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0835","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10040127","article-title":"Responses to the selective bruton's tyrosine kinase (BTK) inhibitor tirabrutinib (ONO\/GS-4059) in diffuse large B-cell lymphoma cell lines","volume":"10","author":"Kozaki","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2019.104389_bib0840","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/rheumatology\/ker448","article-title":"IL-7 drives Th1 and Th17 cytokine production in patients with primary SS despite an increase in cd4 t cells lacking the IL-7R\u03b1","volume":"51","author":"Bikker","year":"2012","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1016\/j.phrs.2019.104389_bib0845","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/243723","article-title":"T regulatory and T helper 17 cells in primary Sj\u00f6gren's syndrome: facts and perspectives","author":"Alunno","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.phrs.2019.104389_bib0850","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaut.2009.10.004","article-title":"Characteristics of the minor salivary gland infiltrates in Sj\u00f6gren's syndrome","volume":"34","author":"Christodoulou","year":"2010","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.phrs.2019.104389_bib0855","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/3877","article-title":"Defective IL7R expression in T-B+ NK+ severe combined immunodeficiency","volume":"20","author":"Puel","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2019.104389_bib0860","doi-asserted-by":"crossref","first-page":"E1761","DOI":"10.1073\/pnas.1222303110","article-title":"Soluble IL7R potentiates IL-7 bioactivity and promotes autoimmunity","volume":"110","author":"Lundstrom","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.phrs.2019.104389_bib0865","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaut.2013.06.007","article-title":"Interleukin-7: fuel for the autoimmune attack","volume":"45","author":"Dooms","year":"2013","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.phrs.2019.104389_bib0870","doi-asserted-by":"crossref","first-page":"10961","DOI":"10.1073\/pnas.1005641107","article-title":"Expansion of human NK-22 cells with IL-7, IL-2, and IL-1 reveals intrinsic functional plasticity","volume":"107","author":"Cella","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.phrs.2019.104389_bib0875","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1136\/annrheumdis-2016-209236","article-title":"High soluble IL-7 receptor expression in Sj\u00f6gren's syndrome identifies patients with increased immunopathology and dryness","volume":"75","author":"Hillen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0880","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/art.27318","article-title":"Increased expression of interleukin-7 in labial salivary glands of patients with primary sj\u00f6gren's syndrome correlates with increased inflammation","volume":"62","author":"Bikker","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104389_bib0885","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1136\/annrheumdis-2011-200744","article-title":"Increased interleukin (IL)-7R\u03b1 expression in salivary glands of patients with primary Sjogren's syndrome is restricted to T cells and correlates with IL-7 expression, lymphocyte numbers and activity","volume":"71","author":"Bikker","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104389_bib0890","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1016\/j.bbadis.2018.04.010","article-title":"Anti-IL-7 receptor-\u03b1 treatment ameliorates newly established Sj\u00f6gren's-like exocrinopathy in non-obese diabetic mice","volume":"1864","author":"Zhou","year":"2018","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2019.104389_bib0895","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2353\/ajpath.2009.090319","article-title":"Systemic and local interleukin-17 and linked cytokines associated with Sj\u00f6gren's syndrome immunopathogenesis","volume":"175","author":"Katsifis","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2019.104389_bib0900","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni1263","article-title":"A function for interleukin 2 in Foxp3-expressing regulatory T cells","volume":"6","author":"Fontenot","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0905","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.01755","article-title":"IL-2 inhibition of Th17 generation rather than induction of treg cells is impaired in primary Sj\u00f6gren's syndrome patients","volume":"9","author":"Luo","year":"2018","journal-title":"Front. Immunol."},{"issue":"Suppl","key":"10.1016\/j.phrs.2019.104389_bib0910","article-title":"Low-dose IL-2 promotes the proliferation of peripheral regulatory T cells in primary Sjogren's syndrome to restore its balances with pro-inflammatory lymphocytes \u2013 ACR Meeting Abstracts","volume":"70","author":"Miao","year":"2018","journal-title":"Arthrits Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0915","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/1529-0131(200111)44:11<2633::AID-ART443>3.0.CO;2-9","article-title":"Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sj\u00f6gren's syndrome","volume":"44","author":"Amft","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104389_bib0920","first-page":"2044","article-title":"Serological implications of germinal center-like structures in primary Sj\u00f6gren's syndrome","volume":"34","author":"Jonsson","year":"2007","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0925","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3346\/jkms.2016.31.2.190","article-title":"The significance of ectopic germinal centers in the minor salivary gland of patients with Sj\u00f6gren's syndrome","author":"Lee","year":"2016","journal-title":"J. Kor. Med. Sci."},{"key":"10.1016\/j.phrs.2019.104389_bib0930","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nri3700","article-title":"Ectopic lymphoid-like structures in infection, cancer and autoimmunity","volume":"14","author":"Pitzalis","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0935","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cytogfr.2011.11.007","article-title":"Biology and signal transduction pathways of the Lymphotoxin-\u03b1\u03b2\/LT\u03b2R system","volume":"22","author":"Remouchamps","year":"2011","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.phrs.2019.104389_bib0940","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00047","article-title":"Role of the lymphotoxin\/LIGHT system in the development and maintenance of reticular networks and vasculature in lymphoid tissues","volume":"5","author":"Lu","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2019.104389_bib0945","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3507","article-title":"Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sj\u00f6gren's syndrome","volume":"13","author":"Fava","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2019.104389_bib0950","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.40513","article-title":"Clinical efficacy and safety of baminercept, a lymphotoxin \u03b2 receptor fusion protein, in primary Sj\u00f6gren's syndrome: results from a phase ii randomized, double-blind, placebo-controlled trial","volume":"70","author":"St.Clair","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104389_bib0955","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nm.3842","article-title":"Homeostatic regulation of T cell trafficking by a B cell-derived peptide is impaired in autoimmune and chronic inflammatory disease","volume":"21","author":"Chimen","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2019.104389_bib0960","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1136\/annrheumdis-2018-eular.7486","article-title":"AB0157 targeting t-cell trafficking in a murine model of Sj\u00f6gren's syndrome","volume":"77","author":"Campos","year":"2018","journal-title":"Ann. Rheum. Dis."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819310424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819310424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:08:56Z","timestamp":1760911736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819310424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":192,"alternative-id":["S1043661819310424"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104389","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics in Sj\u00f6gren's syndrome","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104389","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104389"}}